Comparative Pharmacology
Head-to-head clinical analysis: BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE versus ORGATRAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE versus ORGATRAX.
BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE vs ORGATRAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bromodiphenhydramine hydrochloride is a first-generation antihistamine that antagonizes histamine H1 receptors, reducing allergic symptoms. Codeine phosphate is an opioid agonist at mu-opioid receptors, producing analgesia and antitussive effects. Combination provides enhanced cough suppression.
ORGATRAX (letermovir) inhibits the cytomegalovirus (CMV) DNA terminase complex, preventing viral DNA processing and packaging.
5 mL of oral solution (containing bromodiphenhydramine hydrochloride 12.5 mg and codeine phosphate 10 mg) every 4-6 hours as needed; maximum 4 doses in 24 hours.
Hydroxyzine pamoate (Orgatrax) 25-100 mg orally every 6-8 hours as needed; maximum 600 mg/day.
None Documented
None Documented
Codeine: 2.5-3.5 h (adults), prolonged in hepatic impairment. Diphenhydramine: 4-8 h (adults), extended in elderly.
Terminal elimination half-life is 6–8 hours in adults with normal renal and hepatic function. In elderly patients or those with hepatic impairment, half-life may be prolonged up to 12–15 hours, requiring dose adjustment.
Renal: 70-80% as metabolites (codeine ~10% unchanged; diphenhydramine <5% unchanged). Biliary/fecal: 20-30%.
Primarily hepatic metabolism with renal excretion of metabolites. Approximately 30% of a dose is excreted unchanged in urine; the remainder is eliminated via feces (biliary excretion) after glucuronidation in the liver.
Category A/B
Category C
Antihistamine
Antihistamine